Stoke Therapeutics, Inc.

The 2026 Registration Statement contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of its common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, subscription rights to purchase common stock, preferred stock or debt securities and/or units consisting of some or all of these securities; and a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 150.0 million of its common stock that may be issued and sold under the Sales Agreement.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

As of the issuance date of these unaudited condensed consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve months from the issuance date of these unaudited condensed consolidated financial statements.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

The discount rate used to determine the present value of the lease payments is the Company s incremental borrowing rate based on the information available at lease inception, as the Company did not have information to determine the rate implicit in the leases.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome.

SEC original ↗Stoke Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

( Acadia ), our future results of operations and financial position, business strategy, prospective products, planned preclinical studies and clinical or field trials, regulatory approvals, research and development costs, and timing and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

The Acadia Agreement focused on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Chief Medical Officer​ Current Treatments for Dravet Aim to Reduce Seizures But Do Not Treat the Cognitive and Behavioral Challenges Bromide Clobazam Fenfluramine Stiripentol Valproate Cannabinoid Diazepam Levetiracetam Topiramate Zonisamide ?

SEC original ↗Stoke Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 12, 2025

Difficulties with balance, walking, and gait Seizures Developmental deficits Behavioral changes Sleep disruptions Communication and speech challenges Polytherapy Stress Financial burden Work productivity Social isolation Mental health strain Family dynamics All aspects of life are affected, not only for the individual living with DS, but for their caregivers and families Development in Patients with Dravet Syndrome Differs Markedly from that of Neurotypical Children Comparison of developmental trajectory between neurotypical children and patients with Dravet syndrome Graph provided for illustrative purposes only.

SEC original ↗Stoke Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 12, 2025

Legal Proceedings 31 Item 1A.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part I.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Uncertainties The Company is subject to risks and uncertainties common to late-stage clinical companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Litigation The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which it is focused.

SEC original ↗Stoke Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026